Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
14,242
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
stocks
Higher interest rates boost earnings for ASX real estate platform
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,890.90 | 17.90 | 0.20% |
| CAC 40 | 7,979.92 | 76.46 | -0.95% |
| DAX 40 | 23,954.93 | 395.35 | -1.62% |
| Dow JONES (US) | 49,760.56 | 56.09 | 0.11% |
| FTSE 100 | 10,265.32 | 4.11 | -0.04% |
| HKSE | 26,280.12 | 67.79 | -0.26% |
| NASDAQ | 26,088.20 | 185.92 | -0.71% |
| Nikkei 225 | 62,930.20 | 187.63 | 0.30% |
| NZX 50 Index | 13,024.37 | 55.96 | -0.43% |
| S&P 500 | 7,400.96 | 11.88 | -0.16% |
| S&P/ASX 200 | 8,644.20 | 13.20 | 0.15% |
| SSE Composite Index | 4,213.01 | 1.48 | -0.04% |